BioVaxys

Etobicoke, Canada

BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.

$1.4M raised

Oct 2025

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has BioVaxys raised?

BioVaxys has raised $1.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.

Who are BioVaxys's investors?

BioVaxys's investors include THECCSGROUP, James Passin, Kenneth Kovan.

Where is BioVaxys headquartered?

BioVaxys is headquartered in Etobicoke, Canada.

What does BioVaxys do?

BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.

What stage is BioVaxys at?

BioVaxys is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 7, 2025.

MLA

"BioVaxys — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/biovaxys. Accessed July 2, 2026.

APA

VCBacked. (2025). BioVaxys — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/biovaxys

Wikipedia (cite web)

{{cite web |title=BioVaxys — Funding & Investors |url=https://www.vcbacked.co/company/biovaxys |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 7, 2025.